Combined use of Anlotinib with chemotherapy in patients with advanced ovarian cancer: a real-world cohort study and meta-analysis.

ABSTRACT:

Background

Anlotinib is a novel oral small-molecule receptor tyrosine kinase inhibitor. However, the efficacy and safety of its combined use with chemotherapy remain unclear in patients with advanced ovarian cancer.

Objectives

To assess the efficacy and safety of the combined use of Anlotinib with chemotherapy in patients with advanced ovarian cancer.

Design

A multi-center retrospective real-world analysis and a meta-analysis.

Data sources and methods

We enrolled patients with advanced ovarian cancer who received a combination therapy of Anlotinib and chemotherapy from 15 medical centers. We also searched electronic databases for studies assessing the efficacy and safety of the combined use of Anlotinib with chemotherapy in patients with ovarian cancer. The out

SUBMITTER: Hong X 

PROVIDER: S-EPMC10771750 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature